Nordic Nanovector ASA (OSE: NANO) announces that its management team will present a corporate overview and host one-on-one meetings with investors at the Pareto Securities 11 th Healthcare Conference, taking place 2 nd -3 rd September 2020 . The presentation will take place at 15:00hrs CEST on Thursday, 3 rd September. Th
| OSLO, Norway, Sept. 1, 2020 /PRNewswire/ -- Nordic NanovectorASA (OSE: NANO) announces that its management team will present a corporate overview and host one-on-one meetings with investors at the Pareto Securities 11th Healthcare Conference, taking place 2nd-3rd September 2020. The presentation will take place at 15:00hrs CEST on Thursday, 3rd September. The company presentation will be available on Nordic Nanovector’s Investors and Media page at the same time. About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets. Further information can be found at www.nordicnanovector.com For further information, please contact: Media Enquiries This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. This information was brought to you by Cision http://news.cision.com
SOURCE Nordic Nanovector | ||
Company Codes: Berne:8NN, Bloomberg:NANO@NO, ISIN:NO0010597883, LSE:0R6Y, Oslo:NANO, RICS:NANO.OL, Stockholm:NANOO, Dusseldorf:8NN, Frankfurt:8NN, Stuttgart:8NN |
View original content:
